Vol 6, Supplement 6 (August 29, 2017): Translational Cancer Research


Inhibiting C5a/C5aR axis reduces myeloid-derived suppressor cells and enhances PD-1 blockade therapy in lung cancer
Sherven Sharma, Steven Dubinett
New incriminating evidence against IGF2
Wen Ding, Lina A. Shehadeh
Cancer prevention through better sleeping habits: the circadian clock and hepatocellular cancer
Katarzyna Trebska-McGowan, Trevor W. Reichman
From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein
Felicia L. Lenzo, William G. Cance
Treatment of elderly patients with glioblastoma: new lessons from CE.6
Toral R. Patel, Ankur R. Patel, Sunit Das
The importance of novel molecular biomarker of early stage lung adenocarcinoma
Hideki Ujiie, Kazuhiro Yasufuku
Synergizing genome editing and cancer immunotherapy
Richard Gabriel, Friederike Knipping, Christof von Kalle
Postoperative chemoradiotherapy for elderly patients with glioblastoma: worsening frailty or increasing survival?
Valentina Pinzi
REGATTA trial: its achievement and the issues unsolved
Seung-Young Oh, Hyuk-Joon Lee
Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma
Aaron D. DeWard, Rebecca J. Critchley-Thorne
Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer
Egesta Lopci, Sabrina Rossi
Radiotherapy benefits outweigh risks for breast cancer in modern era
Chih-Jen Huang, Hsin-Hua Lee
A role for lnc-DILC in liver cancer stem cells
Tengfei Zhou, Fang Wang
BRCA1 and BRCA2: two genes, multiple clinical applications
Ekatherina Sh. Kuligina, Evgeny N. Imyanitov
Vesicular control of metastasis: entrap the “virtuous” and free the “wicked” microRNA
Fahd Al-Mulla
CAR-T cell in vivo tracking method using PET scan with the reporter gene and new investigational tracer [18F] FHBG
Tsubasa Miyazaki, Hitoshi Aiyama, Eiichi Ishikawa
Post-operative seizure prophylaxis in gliomas
Andrew Neal, Patrick Kwan, Andrew Morokoff, Terence John O’Brien
Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?
Godefridus J. Peters, Ittai B. Muller, Elisa Giovannetti
Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance?
Pina Ziranu, Francesco Atzori, Marco Puzzoni, Laura Demurtas, Giorgio Astara, Mario Scartozzi
The need for speed: how PD1-blockade only works if T cells are properly activated
Johannes vom Berg, Sebastian Kobold
Elderly patients with glioblastoma: where are we going?
Giuseppe Lombardi, Ardi Pambuku, Vittorina Zagonel
Would the skyrocketed advances of immune checkpoint inhibitors over chemotherapy be stumbled by the safety issues?
Kyrillus S. Shohdy, Omar Abdel-Rahman
The “eyes” have it?—intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay
Steven G. Gray, Mark C. Wright, Stephen P. Finn
Prophylactic cranial irradiation for extensive-stage small-cell lung cancer: an evolving view
Ethan B. Ludmir, Steven H. Lin
Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients
Cinta Hierro, Maria Alsina, Josep Tabernero
Exosome mediated phenotypic changes in lung cancer pathophysiology
Yoshihisa Shimada, John D. Minna
Intensity modulated radiotherapy for head-and-neck cancer: discussing safety of modern radiation techniques
Julie van der Veen, Sandra Nuyts
Perspective on long noncoding RNA functionality
Agnik Haldar, Sanga Mitra, Jayprokas Chakrabarti
Tenascin-C a novel regulator of brain tumor-initiating cells (BTIC) in glioma acts through NOTCH
Juliano Andreoli Miyake, Marc Vooijs
Tenascin-C induces expression of the Notch ligand Jagged1 to promote glioma growth
Elena Parmigiani, Verdon Taylor, Claudio Giachino
Avelumab: a promising PD-L1 inhibitor for lung cancer (with inconvenient infusional reactions)
Tawee Tanvetyanon
Back into focus: tumour-associated macrophages and their role in immune checkpoint inhibition
Sebastian Marwitz, Torsten Goldmann
Lymph node metastasis in oesophageal cancer—what we (do not) know?
Janusz Włodarczyk, Jarosław Kużdżał
Brigatinib entering the clinic for ALK rearranged metastatic NSCLC: editorial on a randomized multicenter phase II study with two brigatinib dose regimens
Adrianus J. de Langen
Ceritinib in ROS1-positive non-small cell lung cancer patients: does clinical evidence carry clinical impact?
Francesco Facchinetti, Marcello Tiseo
Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28
Leonardo Chicaybam, Prasad S. Adusumilli
Unraveling bio-social hierarchy in cancer collective invasion: symbiosis between leaders and followers
Fransisca Leonard, Biana Godin
Deferoxamine may enhance 5-aminolevulinic acid-based fluorescence in glioma surgery
Hirohito Yano, Jun Shinoda, Toru Iwama
Tumor microenvironments of NSCLC are more heterogeneous than you would think—supported by image analysis-based assessment of PD-L1 and tumor-associated immune cell densities
Mari Mino-Kenudson
Diffuse intrinsic pontine gliomas: the future of combination therapy with mTORC1/2 inhibitors and radiation
Idoia Garcia, Juncal Aldareguia, Ander Matheu
Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes
Lucia Lisi, Grazia Graziani, Pierluigi Navarra
Epigenetic profiling of tumor infiltrating lymphocytes
Jill E. Slansky, Laura D. Harmacek, Brian P. O’Connor


This supplement was published without any sponsorship or funding.